EPIDEMIOLOGY AND SURVIVAL OF PATIENTS WITH MALIGNANT TUMORS OF CONNECTIVE AND SOFT TISSUE

Introduction. Malignant tumors of connective and soft tissue are met relatively rare, although in general in Russia each year more than 1.500 new cases are registered. On five administrative territories of Russia during a year there are recorded less than 5 new cases of malignant tumors of connective and soft tissue (Yamal-Nenets A.R. – 4; Tuva Republic – 0, Magadan Region – 3; Chukotka A.R. – 0; Jewish A.R. – 4. More seldom data on these patients’ survival are published. Purpose of study. To estimate dynamics of incidence of malignant tumors of connective and soft tissue on the basis of public reporting, to calculate the index accuracy and observed and relative survival rates by histological forms, including sarcomas. Material and methods. To perform a detailed study there were selected, for two periods of observation, respectively 1054 patients (1995–2001) and 919 patients (2002–2008). Estimation of survival was carried out using software, which had been developed together with Ltd. «Novel» (Director – T.L.Tsvetkova, Ph.D.). results of study. The most typical incidence rate for of malignant tumors of connective and soft tissue (S47, 49) that are presented by  cancer registries of different countries is from 1.5 to 2.5 0/   in men and 1.5–2.0 0/   in women. Dynamics  of morbidity of the Russian population, Moscow and St. Petersburg indicates that the level of standardized  incidence rates is in the range of 2.0 0/   in men and within 1.5 0/   in women. The mortality rate in 2013  was respectively for men and women in Russia in total 1.7 0/   and 1.13 0/   , in Moscow – 1.42 0/   and  1.24 0/   , in St. Petersburg – 1.88 0/   and 1.26 0/   . The index accuracy for both sexes in Russia is 0.88,  in Moscow – 1.2; in St. Petersburg – 1.4. This index should be used for the site of these diseases with high fatality. According to official data a one-year lethality of patients with tumors of connective and soft tissue in 2013 was 20.1 %, and for all malignant tumors – 25.3 %, however the index accuracy for all malignant tumors was equal to 0.72, and for malignant tumors of connective and soft tissue – 0.88. That is in 5 of 8 federal districts the index accuracy is 1 or more, testifies significant undercount of patients with malignant tumors of connective and soft tissue. conclusion. The study allowed determining, despite relatively low rates of morbidity and mortality from malignant tumors of connective and soft tissue, there was revealed a significant undercount of primary cases. In a number of federal districts morbidity exceeds morbidity. Kaposi’s sarcoma is a tiny fraction of this group of tumors. The main part of patients with malignant tumors of connective and soft tissue is for C49 column «Malignant tumors of other types of connective and soft tissue». In basic part of patients with malignant tumors of connective and soft tissue there has been established positive dynamics of a 5-year observed and relative survival but this level is lower than the European average. Among sarcomas all malignant tumors of connective and soft tissue the best indicator of survival is for liposarcoma (>70 %), then for leiomyosarcoma (>40 %), and the least for sarcoma with undefined diagnosis.

malignant tumors of connective and soft tissue, epidemiology, survival, index accuracy

1. Malignant tumors in Russia in 2013 (morbidity and mortality) / Eds. A.D. Kaprin, V.V. Starinskiy, G.V. Petrova. M., 2015. 250 p. [in Russian]

2. Ivanov O.A., Sukharev A.E., Starinskiy V.V., Egorov S.N. Processing method database (survival): methodical recommendations. M., 1997. 32 p. [in Russian]

3. Merabishvili V.M. The survival of cancer patients. SPb., 2006. 440 p. [in Russian]

4. Merabishvili V.M. Survival of cancer patients / Ed. Yu.A. Shcherbuk. SPb., 2011. Issue 2. Part 1. 332 p. [in Russian]

5. Merabishvili V.M. Survival of cancer patients / Ed. Yu.A. Shcherbuk. SPb., 2011. Issue 2. Part 2. 408 p. [in Russian]

6. Merabishvili V.M. Cancer control in St. Petersburg (operative report for 2011-2012, precise elaboration of registry`s data base in accordance with internationals standarts). Population-based Cancer Registry (IACR № 221) Sci publ. № 18 / Ed. V.M. Kolabutin, A.M. Belyaev. SPb., 2013. 368 p.[in Russian]

7. Merabishvili V.M. Oncological Statistics (traditional methods, new information technologies). Guidelines for physicians. SPb., 2011. Part II. 224 p. [in Russian]

8. Merabishvili V.M. Oncological Statistics (traditional methods, new information technologies). Guidelines for physicians. SPb., 2011. Part II. 248 p. [in Russian]

9. Organization and operation of the population cancer registry: methodical recommendations. M., 2001. 13 p.[in Russian]

10. The basic principles of selection and coding underlying cause of death in patients with malignant tumors: methodical recommendations. M., 2002. 37 p. [in Russian]

11. The state of cancer care the population of Russia in 2013 / Eds. A.D. Kaprin, V.V. Starinskiy, G.V. Petrova. M., 2015. 235 p. [in Russian]

12. Starinskiy V.V., Petrova G.V., Gretsova O.P., Kharchenko N.V., Merabishvili V.M. Improving the forms of federal statistical reporting on oncology // Povolozhskiy onkologicheskiy vestnik. 2001. № 1. P. 88-89. [in Russian]

13. Cancer incidence in five continents. Vol. I-IX. URL : http://www. ci5.iarc.fr/C151-IX/C15i-ix.htm (25.02.2015).

14. Richards M. Eurocare 4 studies bring new data of cancer survival // Lancet oncol. 2007. Vol. 8 (9). P. 752-753.

15. Survay of Cancer patients in Europe: the Eurocare-3 Study / Ed. F. Berrino et al. // Annals of Oncology. Oxford press, 2003. Vol. 14. Supplement 5.

16. Survival of cancer patients in Europe / Ed. F. Berrino et al. IARC Sci. publ. № 132. Lyon, 1995. 465 p.

17. Survival of cancer patients in Europe : the Eurocare-2 Study / Ed. F. Berrino et al. IARC Sci. publ. № 151. Lyon, 1999. 572 p.

18. Verdecchia A., Francisci S., Brenner H., Gatta G., Micheli A., Mangone L., Kunkler I. Recent cancer survival in Europe: a 2000-2002 period analysis of Eurocare-4 data // Lancet oncol. 2007. Vol. 8 (9). P. 784-796.